Duravulumab (trade name Imfinzi) is a humanized antibody that can directly target PD-L1, blocking the interaction between PD-L1 and PD-1, thereby preventing tumor immune evasion and enhancing the immune responses [355]. This evidence concerns the gene CD274 and neoplasm.